Today, Evercore ISI analyst Mark Schoenebaum trumpeted his belief that Axovant, which bought a discarded 5-HT6 inhibitor from GlaxoSmithKline for $5 million and flipped it into a public biotech months later with a market cap now hovering around $1.9 billion, has a 65% chance of success in an upcoming Phase III study.
You can score another setback for Roche's star-crossed attempt to develop a new drug for Alzheimer's. Roche partner Evotec reported that their drug sembragiline failed a Phase IIB study. Sembragiline is a MAO-B inhibitor, a class of drugs which is currently used to treat Parkinson's disease. The drug is designed to safeguard dopamine by targeting an enzyme--monoamine oxidase type B, or MAO-B--that breaks it down. But investigators say the drug failed to demonstrate a cognitive benefit in patients after 52 weeks of therapy. Read more >>
Welcome to the latest edition of our weekly EuroBiotech Report. Actelion bet €30 million ($33 million) on the potential of synthetic carbohydrate vaccines. The arrangement sees Actelion become the majority shareholder in a biotech created to develop assets discovered at the Max Planck Society, giving it exposure to the vaccine field without interfering with its core business. Immunocore signed up to have its lead T cell receptor (TCR)-based therapy trialled in another combination study. The latest deal gives Eli Lilly the right to test the TCR therapy in combination with a pair of its small molecules. And more. Read the full report >>
Dr. Nathalie Adda was named CMO of Enanta Pharmaceuticals this week as the company prepares to advance its internal virology and liver disease programs. Adda has more than 15 years of experience in the pharma industry, serving in all phases of global clinical research and development and commercialization, Enanta said in its statement, most recently as the CMO at Transgene. Read more >>
POPULAR COMMENT THREADS
On Thursday, a team from Eli Lilly will take the hot seats in front of an advisory committee meeting of external FDA experts to make a case for necitumumab, another cancer drug which offers only marginal efficacy for advanced patients with a troubling profile for potentially lethal adverse events. And their odds-on chance of succeeding helps explain why this field has become so popular with drug developers.
Allergan has scooped up a med tech startup with an innovative treatment for dry eye disease, paying $125 million up front for the rights to a tiny device designed to spur tear production.
A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores the potential for developing the world's first HIV vaccine.
Versartis has cleared a roadblock in its path to launching a long-acting treatment for growth hormone deficiency, resolving an FDA clinical hold and getting back on track with its Phase III program.
Novo Nordisk has terminated a collaboration deal with Zosano Pharma, walking away from an agreement that would have paired its late-stage diabetes drug with the latter company's microneedle patch technology.
23andMe has filed documents with the SEC stating that it has raised $79 million of a $150 million round. The fundraising comes soon after the company revealed plans to dive into the drug development world, recruiting Genentech's Richard Scheller as its chief scientific officer.
From Our Sister Sites
In a study reported in the journal Science, researchers examine the mechanical engineering involved in the shape of a seahorse's tail. They expect this research could have biomedical implications.
As the market for psoriasis meds heats up, companies are throwing down some hefty chunks of change to snag airtime for their TV spots.